Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $1.9 million.

  • Harvard Bioscience's Accumulated Expenses rose 80.82% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 80.82%. This contributed to the annual value of $1.7 million for FY2024, which is 5637.57% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Accumulated Expenses is $1.9 million, which was up 80.82% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Accumulated Expenses peaked at $6.0 million during Q4 2021, and registered a low of $1.7 million during Q4 2024.
  • Moreover, its 5-year median value for Accumulated Expenses was $3.1 million (2022), whereas its average is $3.1 million.
  • Per our database at Business Quant, Harvard Bioscience's Accumulated Expenses skyrocketed by 7998.2% in 2021 and then crashed by 5637.57% in 2024.
  • Over the past 5 years, Harvard Bioscience's Accumulated Expenses (Quarter) stood at $6.0 million in 2021, then crashed by 42.53% to $3.5 million in 2022, then increased by 13.03% to $3.9 million in 2023, then plummeted by 56.38% to $1.7 million in 2024, then grew by 9.16% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $2.1 million for Q2 2025, and $1.9 million during Q1 2025.